US 12,215,151 B2
Methods of treating cancer using antibodies and molecules that immunospecifically bind to BTN1A1
Stephen Sunghan Yoo, Centreville, VA (US); Yong-Sik Bong, Frederick, MD (US); Kyu Lee Han, Frederick, MD (US); and Michael Joseph Surace, Germantown, MD (US)
Assigned to STCUBE & CO., INC., Seoul (KR)
Appl. No. 16/618,050
Filed by STCUBE & CO., INC., Seoul (KR)
PCT Filed May 30, 2018, PCT No. PCT/US2018/035082
§ 371(c)(1), (2) Date Nov. 27, 2019,
PCT Pub. No. WO2018/222685, PCT Pub. Date Dec. 6, 2018.
Claims priority of provisional application 62/513,393, filed on May 31, 2017.
Prior Publication US 2020/0131266 A1, Apr. 30, 2020
Int. Cl. A61K 39/395 (2006.01); A61N 5/10 (2006.01); A61P 35/00 (2006.01); C07K 16/28 (2006.01); G01N 33/574 (2006.01); A61K 39/00 (2006.01)
CPC C07K 16/2803 (2013.01) [A61N 5/10 (2013.01); A61P 35/00 (2018.01); C07K 16/2818 (2013.01); C07K 16/2827 (2013.01); G01N 33/57415 (2013.01); G01N 33/57423 (2013.01); A61K 2039/505 (2013.01); A61K 2039/507 (2013.01); C07K 2317/565 (2013.01); C07K 2317/73 (2013.01); C07K 2317/76 (2013.01); C07K 2317/92 (2013.01); G01N 2333/70532 (2013.01)] 20 Claims
 
1. A method of treating cancer in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of a molecule comprising an antigen binding fragment that immunospecifically binds to BTN1A1, wherein the cancer expresses PD-L1 at a level lower than or equal to a PD-L1 reference level; wherein the PD-L1 reference level is the average or medium expression level of PD-L1 in a population of healthy individuals; and wherein the antigen binding fragment comprises:
(i) a heavy chain variable region (VH) comprising a VH complementarity-determining region (CDR) 1, a VH CDR2, and a VH CDR3 having an amino acid sequence of a VH CDR1, a VH CDR2, and a VH CDR3, respectively, of a VH having an amino acid sequence of SEQ ID NO:31; and
(ii) a light chain variable region (VL) comprising a VL CDR1, a VL CDR2, and a VL CDR3 having an amino acid sequence of a VL CDR1, a VL CDR2, and a VL CDR3, respectively, of a VL having an amino acid sequence of SEQ ID NO:33.